Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy

Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy

Autor Martins, JRM Google Scholar
Furlanetto, R. P. Google Scholar
Oliveira, L. M. Google Scholar
Mendes, A. Google Scholar
Passerotti, C. C. Google Scholar
Chiamolera, M. I. Google Scholar
Rocha, A. J. Google Scholar
Manso, P. G. Google Scholar
Nader, H. B. Google Scholar
Dietrich, C. P. Google Scholar
Maciel, RMB Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Fleury Diagnost Ctr
Resumo OBJECTIVE Immunosuppressive treatment of Graves' opthalmopathy (GO) should be restricted to patients with active eye disease, but assessing disease activity is difficult. Several methods to evaluate GO activity have been introduced, but none of them is satisfactory. Glycosaminoglycans (GAGs) are complex polysaccharides that participate on the pathogenesis of GO and attempts to correlate its local increase to urinary GAGs (uGAGs) or serum hyaluronan (sHA) have been made, but the available techniques are labourious, time-consuming and difficult for routine use. the aim of the present study is to develop practical and simple methods for uGAGs and sHA and compare them to the activity and severity of thyroid-associated ophthalmopathy.DESIGN, PATIENTS and MEASUREMENTS We developed a microelectrophoresis technique for uGAGs and a fluoroassay for sHA and assessed each in 152 patients with Graves' disease, 25 without GO and 127 with GO, classified according to the Clinical Activity Score (CAS). All patients had been euthyroid for > 2 months.RESULTS Patients with inactive disease (CAS = 2, n = 100) had uGAGs (4.2 +/- 1.3 mug/mg/creatinine) and sHA (11.1 +/- 7.2 mug/l) that did not differ from normal subjects (3.1 +/- 1.1 mug/mg/creatinine, n = 138 and 13.9 +/- 9.6 mug/l, n = 395). in contrast, patients with active eye disease (CAS = 3, n = 27) had uGAGs (8.4 +/- 2.7 mug/mg/creatinine) and sHA (32.3 +/- 17.8 mug/l) 2-3 times higher than those patients with inactive eye disease. Using a cut-off of 6.1 mug/mg creatinine for uGAGs and 20.7 mug/l for sHA we found, respectively, 85% and 81% sensitivity and 93% and 91% specificity for each test. the positive and negative predictive values were 77% and 96% for uGAGs and 71% and 95% for sHA.CONCLUSION Employing these two new methods we have established a significant relationship between the levels of uGAGs and/or sHA and the clinical activity of GO. Therefore, together with CAS, uGAGs determination, and, to a lesser degree, sHA, would be very useful in the discrimination from active and inactive ocular disease and aid in deciding on the best therapy for GO patients.
Idioma Inglês
Data de publicação 2004-06-01
Publicado em Clinical Endocrinology. Oxford: Blackwell Publishing Ltd, v. 60, n. 6, p. 726-733, 2004.
ISSN 0300-0664 (Sherpa/Romeo, fator de impacto)
Publicador Blackwell Publishing Ltd
Extensão 726-733
Fonte http://dx.doi.org/10.1111/j.1365-2265.2004.02044.x
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000221644800011
Endereço permanente http://repositorio.unifesp.br/handle/11600/27787

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta